The estimated Net Worth of James F Brown is at least $124 Tisíc dollars as of 4 January 2022. Mr. Brown owns over 28,384 units of Bellicum Pharmaceuticals Inc stock worth over $2,122 and over the last 10 years he sold BLCM stock worth over $0. In addition, he makes $121,550 as Independent Chairman of the Board at Bellicum Pharmaceuticals Inc.
James has made over 1 trades of the Bellicum Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 28,384 units of BLCM stock worth $2,122 on 4 January 2022.
The largest trade he's ever made was exercising 28,384 units of Bellicum Pharmaceuticals Inc stock on 4 January 2022 worth over $2,122. On average, James trades about 2,580 units every 0 days since 2014. As of 4 January 2022 he still owns at least 28,384 units of Bellicum Pharmaceuticals Inc stock.
You can see the complete history of Mr. Brown stock trades at the bottom of the page.
James Farrell Brown J.D. serves as Independent Chairman of the Board of the Company. He has served as a member of our Board since November 2011 and as Chairman of our Board since December 2014. From July 2009 to May 2017 he has served as Managing Director of AVG Ventures, a private investment firm. From 2003 to 2009, Mr. Brown was an independent investor and served on a number of private company boards of directors. From 1999 to 2002, he served as Executive Vice President and General Manager of OpenTV, Inc., a technology and media company, where he co-founded and managed the company’s applications business unit, prior to its sale to Liberty Media in 2002. Earlier in his career, Mr. Brown was a partner in the law firms of McDermott, Will & Emery and Pillsbury Madison & Sutro. Mr. Brown is currently a director of Landmark Infrastructure Partners, LP, a public real estate management company. He also served as a director of Perk.com, Inc., a public company traded on the Toronto Stock Exchange, from July 2015 to January 2017. He received his B.S. in accounting from Weber State University and his J.D. from Brigham Young University School of Law. Our Board believes that Mr. Brown’s business experience and his success as an investor and entrepreneur qualify him to serve on our Board.
As the Independent Chairman of the Board of Bellicum Pharmaceuticals Inc, the total compensation of James Brown at Bellicum Pharmaceuticals Inc is $121,550. There are 4 executives at Bellicum Pharmaceuticals Inc getting paid more, with Richard Fair having the highest compensation of $1,732,890.
James Brown is 55, he's been the Independent Chairman of the Board of Bellicum Pharmaceuticals Inc since 2014. There are 6 older and 10 younger executives at Bellicum Pharmaceuticals Inc. The oldest executive at Bellicum Pharmaceuticals Inc is Dr. Alan K. Smith Ph.D., 63, who is the Chief Scientific Officer.
James's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, SUITE 1200, HOUSTON, TX, 77098.
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... a Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: